VLST Corporation announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody. CP-870,893 is a potent CD40 agonist that has been evaluated in a number of preclinical and clinical trials to date. These studies have determined the safety profile, pharmacokinetics and pharmacodynamic parameters of CD40-mediated immune activation as well as the maximum tolerated dose of the antibody. VLST plans to advance this compound into efficacy studies in an oncology setting. VLST is currently evaluating multiple clinical opportunities. Under the terms of the agreement, Pfizer will retain co-exclusive rights to CP-870,893 in the oncology vaccine field.

VLST Corporation Presents at BIO International Convention 2011, Jun-29-2011 10:15 AM. Venue: The Walter E. Washington Convention Center, The Adams Morgan Room, Washington, District Of Columbia, United States.

VLST Corporation announced the appointment of Brian Blackman as Vice President, Finance and Administration. Blackman joins the company from BN ImmunoTherapeutics Inc. where he served as director, business operations since 2008. Prior to that, Blackman was senior manager, business development for Dendreon Corporation from 2005 to 2008, joining Dendreon in 2004 as senior area finance manager. His career in financial management has also included work at Penton Media Inc., as senior financial analyst and Amgen Inc., serving as financial analyst for Amgen Colorado. Blackman received a B.S. in Finance from the University of Colorado at Boulder and an M.B.A. from London Business School, UK.